Allergy shots for dust mites in teens and adults
Part of Ear, nose & throat, Immune system & allergy, Lungs & breathing clinical trials.
This Phase 3 study tests whether dust-mite allergy treatment (likely allergy shots) can reduce allergy symptoms and improve safety. It focuses on people whose nose/eye allergy is triggered by house dust mites and who may also have controlled asthma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) are age 12 to 65 and can follow trial visits and instructions
- You have confirmed dust-mite allergy (from testing) and symptoms like ongoing or recurring nose and eye allergy
- Your allergy skin test is clearly positive for dust mites, and blood allergy tests for dust-mite allergy are above a set level
- If you have asthma, it must be diagnosed at least 12 months before joining and should not be severe or uncontrolled
- You must be able to use a smartphone to record symptoms and medicines during the trial
- You should not have had allergy immunotherapy for mites (or other triggers like dander/fungi) in the last 5 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an under-the-tongue tablet for people with dust mite allergies causing moderate to severe nasal symptoms or mild-to-moderate asthma. The goal is to see if it improves symptoms and can replace or reduce the need for allergy medicines.
This phase 3 trial tests a specific allergy treatment (an “immunotherapy” shot) for people whose symptoms are triggered by grass and cypress tree pollen. It aims to see if the treatment is safer and more effective at reducing allergy symptoms over time, especially for nose/eye symptoms and some people with asthma.
This study uses a small microneedle patch to collect skin-related samples to help predict how well allergy immunotherapy may work. It includes people with house dust mite allergy and also a healthy control group, so researchers can compare biomarker results.
This study compares two allergy treatments for people with moderate asthma caused by dust mites. It tests whether a biologic injection (omalizumab) alone is as effective as combining it with allergy drops under the tongue (sublingual immunotherapy).
This Phase 3 trial tests whether an allergy treatment can reduce symptoms caused by grass and olive pollen. It also checks safety, especially for breathing and allergic reactions, in people with confirmed grass/olive allergy.
This study looks at how sublingual immunotherapy tablets, which are placed under the tongue, affect the body's response to dust mite allergies in people with allergic rhinitis. The goal is to understand how these tablets might change the immune system and help improve symptoms.
Hear when a new Rhinoconjunctivitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.